Aurobindo Pharmaceuticals

Aurobindo Pharma Ltd.

Maitri Vihar, Ameerpet,

Hyderabad – 500 038,

Andhra Pradesh, India.




Email :

Tel: +91 (40) 6672 5000

Fax: +91(40) 2374 1080 / 2374 6883

Company History

Aurobindo Pharma was born of a vision. Founded in 1986 by Mr. P.V.Ramaprasad Reddy, Mr. K.Nityananda Reddy and a small, highly committed group of professionals, the company became a public venture in 1992. It commenced operations in 1988-89 with a single unit manufacturing semi synthetic penicillins (SSPs) at Pondicherry.

Aurobindo Pharma had gone public in 1995 by listing its shares in various stock exchanges in the country. The company is the market leader in semi-synthetic penicillin drugs. It has a presence in key therapeutic segments like SSPs, cephalosporins, antivirals, CNS, cardio-vascular, gastroenterology, etc.

Over the years, the Aurobindo Pharma has evolved into a knowledge driven company. It is R&D focused, has a multi-product portfolio with multi-country manufacturing facilities, and is becoming a marketing conglomerate across the world.

Aurobindo Pharma created a name for itself in the manufacture of bulk actives, its area of core competence. After ensuring a firm foundation of cost effective production capabilities and a clutch of loyal customers, the company has entered the high margin speciality generic formulations segment, with a global marketing network.

The formulation business is systematically organised with a divisional structure, and has a focused team for each key international market. Aurobindo believes in gaining volume and market share in every business/segment it enters.

Aurobindo has invested significant resources in building a mega infrastructure for APIs and formulations to emerge as a vertically integrated pharmaceutical company. Aurobindo’s five units for APIs and four units for formulations are designed for the regulated markets.

Among the largest ‘Vertically Integrated’ pharmaceutical companies in India, Aurobindo has robust product portfolio spread over major product areas encompassing CVS, CNS, Anti-Retroviral, Antibiotics, Gastroenterologicals, Anti-Diabetics and Anti-Allergic with approved manufacturing facilities by USFDA, UKMHRA, WHO, MCC-SA, ANVISA-Brazil for both APIs & Formulations and has Global presence with own infrastructure, strategic alliances, subsidiaries & joint ventures.
Aurobindo’s R & D strengths lie in developing intellectual property in non-infringing processes and resolving complex chemistry challenges. In the process, Aurobindo develops new drug delivery systems, dosage formulations and applies new technology for better processe

Board of Directors

Mr. P.V.Ramaprasad Reddy, (51)

Mr. K.Nityananda Reddy, (51)
Managing Director

Mr. M. Madan Mohan Reddy, (49)
Whole-time Director

Dr. M.Sivakumaran, (66)
Whole-time Director

Mr. M.Sitarama Murthy, (65)
Non-Executive Director

Dr.P.L.Sanjeev Reddy, (69)
Non-Executive Director

Dr. D. Rajagopala Redddy, (51)
Non-Executive Director

Dr. K. Ramachandran, (53)
Non-Executive Director

Mr.K.Ragunathan, (46)
Non-Executive Director

Mr.P.Sarath Chandra Reddy, (24)
Non-Executive Director

2 responses on "Aurobindo Pharmaceuticals"

  1. Perfect short post about the Aurobindo Pharmaceuticals –

    Thank You ! Pharma Crunch

  2. it was good to know about it … trying to get more data on this topics ..will post the updates here .. 🙂 …

Leave a Message

Your email address will not be published. Required fields are marked *


Join fastest growing subscribers who benefit from PharmaCrunch’s coverage on "Pharmaceuticals - Must to Know" updates

Testimonial from Subscribers

Read more

Samanvay Sauraj

Sales Manager - Franco Indian
2016 © PharmaCrunch All rights reserved
Skip to toolbar